Melvin Albert Churchill Jr. MD FACR

Rheumatology•Lincoln, NE

Osteoporosis & Bone Metabolism

Founder Arthritis Center of Nebraska ;Director Physician Research Collaboration

Join to View Full Profile

3901 Pine Lake RdSuite 120Lincoln, NE 68516
Phone+1 402-420-1212
Fax+1 402-328-0961

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Rheumatology, 1977 - 1978
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1973 - 1977
University of Nebraska Medical Center College of MedicineInternship, Internal Medicine, 1972 - 1973
University of Nebraska College of MedicineClass of 1972

Certifications & Licensure

NE State Medical License 1972 - 2026
IA State Medical License 1975 - 1979
MN State Medical License 1973 - 1979
WI State Medical License 1977 - 1978
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2011-2013
Fellow (FACR) American College of Rheumatology

Clinical Trials

Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis Start of enrollment: 2012 Jun 01
Completed
Phase 2
A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus Start of enrollment: 2014 Jan 01
Terminated
Phase 3
A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis Start of enrollment: 2016 May 02
Completed
Phase 3
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis Start of enrollment: 2016 Aug 02
Completed
Phase 3
A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis Start of enrollment: 2017 May 09
Completed
Phase 3
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2) Start of enrollment: 2020 Jul 01
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Contact
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) Start of enrollment: 2020 Jul 01
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Contact
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis Start of enrollment: 2022 Jun 30
RECRUITING
PHASE3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase 3 Study.
Alan Kivitz, Liliana Sedova, Melvin Churchill, Roshan Kotha, Atul Singhal
Arthritis & Rheumatology. 2025-02-01
9 citations
Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study.
Tien Nguyen, Melvin Churchill, Robert Levin, Guillermo Valenzuela, Joseph F Merola
The Journal of Rheumatology. 2022-08-01
13 citations
Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAI...
Tuhina Neogi, David J Hunter, Melvin Churchill, Ivan Shirinsky, Alexander White
Arthritis Research & Therapy. 2022-03-29

Professional Memberships

American Medical Association - AMA
Member
American College of Rheumatology - ACR
Fellow
International Society of Clinical Densitometry
Member